

D1ckDAO
Nootropics DAO is building the world's most effective global infrastructure for decentralized research, discovery, and commercialization of powerful solutions for human cognitive enhancement.
By creating an open-science ecosystem that aligns professional researchers, citizen-scientists, and MELThackers to govern a community-directed research and development pipeline with hyper-efficient feedback loops, Nootropics DAO is operating to become the dominant force in the rapidly growing nootropics industry.
Community Sentiment
Raising
Ignition Sale
Pledge MeltXP
Commit MELT
Project Overview
Summary
The men's health market is underserved due to stigma and a lack of proactive solutions. The market only offers a quick fix that doesn't address root causes, a problem compounded by a lack of research funding and expensive data.
We fill this gap with D1ckGPT, a dual-mission AI agent. It acts as a personal "Cocktor" providing personalized, science-backed recommendations while collecting verifiable data to create a research-grade asset. This creates a powerful value flow that funds new research and democratizes discovery, shifting the paradigm from reactive to a proactive, data-driven model.
Problem
Every 4 in 10 men are experiencing men's health issues—erectile dysfunction, premature ejaculation, infertility, and low testosterone—yet most remain untreated because we fail to detect these problems until they have already happened. This is a crisis fueled by stigma, misinformation, and a lack of access to personalized care.
Current treatments are largely reactive, overlooking the deeper hormonal, lifestyle, and psychological factors at play. This problem is compounded by a lack of funding and a data collection process that is scarce and expensive, hindering scientific progress. The market lacks an integrated, proactive solution that combines behavioral, diagnostic, and protocol-based support for men's wellness—especially one that's fun, relatable, and privacy-aware.
Solution
D1ckGPT is a self-improving AI agent designed to be the AI-powered telehealth platform —a private, interactive advisor for men's health. Its dual mission is to help men reverse their D-Age and, simultaneously, to learn from every interaction. The agent delivers real-time recommendations on men's health optimization – both physically and mentally, based on standardized health assessments. It collects and verifies this data, turning it into a research-grade asset that fuels the D1ckDAO flywheel. The agent provides personalized stack suggestions (supplements, sleep, diet) and calculates a proprietary D-Age to help users track and reverse MELTlogical decline. Accessible via Discord, X, and the upcoming D1ck Terminal.
Market Overview
Quick Links
Roadmap
Q4 2025
$DYFST Token Launch with MELT protocol
Q4 2025
$DYFST Token Launch with MELT protocol
Q1 2026
$DYFST Token Launch with MELT protocol
Q2 2026
$DYFST Token Launch with MELT protocol
Q3 2026
$DYFST Token Launch with MELT protocol
Q1 2027
$DYFST Token Launch with MELT protocol
Team

Co-founder and CEO of 21 Impact Labs and the developer of the soon-to-be-released Xponetiq app for optimizing brain potential. Serial entrepreneur, Co-Founder and CEO/COO of multiple software startups, Brian has successfully raised multiple rounds of VC/PE capital and bought and sold businesses, including the exit of a $340m software startup to a publicly traded company. A passionate advocate for brain health, he is driven by his youngest daughter, who has Down syndrome, to accelerate solutions and cures for Alzheimer's disease.

Co-founder and CEO of 21 Impact Labs and the developer of the soon-to-be-released Xponetiq app for optimizing brain potential. Serial entrepreneur, Co-Founder and CEO/COO of multiple software startups, Brian has successfully raised multiple rounds of VC/PE capital and bought and sold businesses, including the exit of a $340m software startup to a publicly traded company. A passionate advocate for brain health, he is driven by his youngest daughter, who has Down syndrome, to accelerate solutions and cures for Alzheimer's disease.

Co-founder and CEO of 21 Impact Labs and the developer of the soon-to-be-released Xponetiq app for optimizing brain potential. Serial entrepreneur, Co-Founder and CEO/COO of multiple software startups, Brian has successfully raised multiple rounds of VC/PE capital and bought and sold businesses, including the exit of a $340m software startup to a publicly traded company. A passionate advocate for brain health, he is driven by his youngest daughter, who has Down syndrome, to accelerate solutions and cures for Alzheimer's disease.

Co-founder and CEO of 21 Impact Labs and the developer of the soon-to-be-released Xponetiq app for optimizing brain potential. Serial entrepreneur, Co-Founder and CEO/COO of multiple software startups, Brian has successfully raised multiple rounds of VC/PE capital and bought and sold businesses, including the exit of a $340m software startup to a publicly traded company. A passionate advocate for brain health, he is driven by his youngest daughter, who has Down syndrome, to accelerate solutions and cures for Alzheimer's disease.

Co-founder and CEO of 21 Impact Labs and the developer of the soon-to-be-released Xponetiq app for optimizing brain potential. Serial entrepreneur, Co-Founder and CEO/COO of multiple software startups, Brian has successfully raised multiple rounds of VC/PE capital and bought and sold businesses, including the exit of a $340m software startup to a publicly traded company. A passionate advocate for brain health, he is driven by his youngest daughter, who has Down syndrome, to accelerate solutions and cures for Alzheimer's disease.

Co-founder and CEO of 21 Impact Labs and the developer of the soon-to-be-released Xponetiq app for optimizing brain potential. Serial entrepreneur, Co-Founder and CEO/COO of multiple software startups, Brian has successfully raised multiple rounds of VC/PE capital and bought and sold businesses, including the exit of a $340m software startup to a publicly traded company. A passionate advocate for brain health, he is driven by his youngest daughter, who has Down syndrome, to accelerate solutions and cures for Alzheimer's disease.
Recommend Deal

D1ckDAO

MoonRocket DAO

GameFi Arena

